Pluristem Therapeutics (GB:0KJI)
UK Market

Pluristem Stock Analysis & Ratings

GB:0KJI Stock Chart & Stats

Currently, no data available
Please return soon. This page is being updated.



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.



What was Pluristem’s price range in the past 12 months?
Pluristem lowest stock price was $0.00 and its highest was $0.00 in the past 12 months.
    What is Pluristem’s market cap?
    Pluristem’s market cap is $19.25M.
      What is Pluristem’s price target?
      The average price target for Pluristem is $9.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $9.00 ,the lowest forecast is $9.00. The average price target represents 1412.61% Increase from the current price of $0.595.
        What do analysts say about Pluristem?
        Pluristem’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
          When is Pluristem’s upcoming earnings report date?
          Pluristem’s upcoming earnings report date is Feb 07, 2023 which is in 265 days.
            How were Pluristem’s earnings last quarter?
            Pluristem released its earnings results on May 09, 2022. The company reported -$0.306 earnings per share for the quarter, beating the consensus estimate of -$0.31 by $0.004.
              Is Pluristem overvalued?
              According to Wall Street analysts Pluristem’s price is currently Undervalued.
                Does Pluristem pay dividends?
                Pluristem does not currently pay dividends.
                What is Pluristem’s EPS estimate?
                Pluristem’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Pluristem have?
                Pluristem has 32,350,000 shares outstanding.
                  What happened to Pluristem’s price movement after its last earnings report?
                  Pluristem reported an EPS of -$0.306 in its last earnings report, beating expectations of -$0.31. Following the earnings report the stock price went same N/A.
                    Which hedge fund is a major shareholder of Pluristem?
                    Among the largest hedge funds holding Pluristem’s share is ARK Investment Management LLC. It holds Pluristem’s shares valued at N/A.


                      Pluristem Stock Analysis

                      The Pluristem stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Pluristem Therapeutics

                      Pluristem Therapeutics, Inc. engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. It focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.

                      Similar Stocks
                      Price & Change
                      United Therapeutics
                      Capricor Therapeutics

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis